KRAS G12D MUTATIONS
Clinical trials for KRAS G12D MUTATIONS explained in plain language.
Never miss a new study
Get alerted when new KRAS G12D MUTATIONS trials appear
Sign up with your email to follow new studies for KRAS G12D MUTATIONS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug targets 'Undruggable' cancer mutation in major trial
Disease control Recruiting nowThis clinical trial is testing an experimental drug called GFH375 for people with advanced solid tumors that have a specific genetic mutation called KRAS G12D. The study aims to determine if the drug is safe, how it moves through the body, and if it can help shrink tumors. It wil…
Matched conditions: KRAS G12D MUTATIONS
Phase: PHASE1, PHASE2 • Sponsor: Genfleet Therapeutics (Shanghai) Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New drug targets 'Undruggable' mutation in deadly pancreatic cancer
Disease control Recruiting nowThis study is testing an experimental drug called RNK08954 for people with advanced pancreatic cancer that has spread and has a specific genetic change called KRAS G12D. The main goals are to see if the drug is safe and if it can help slow or stop the cancer's growth. It is for a…
Matched conditions: KRAS G12D MUTATIONS
Phase: PHASE2 • Sponsor: Ranok Therapeutics (Hangzhou) Co., Ltd. • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC